Evaluation of a spray-dried dispersion (SDD) formulation of MGCD265, a receptor tyrosine kinase (RTK) inhibitor, in a phase 1 study of patients (pts) with advanced solid tumors

被引：0
|
作者：
Sharma, Sunil
Shapiro, Geoffrey
Kollmannsberger, Christian K.
Christensen, James
Tassell, Vanessa Roberts
Faltaos, Demiana
Chao, Richard C.
Hurwitz, Herbert
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e14087
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14087
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase I study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced solid tumors.
    Kollmannsberger, Christian K.
    Sharma, Sunil
    Shapiro, Geoffrey
    Chi, Kim N.
    Christensen, James
    Tassell, Vanessa Roberts
    Chao, Richard C.
    Faltaos, Demiana
    Hurwitz, Herbert
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR, in combination with erlotinib in patients with advanced solid tumors.
    O'Dwyer, Peter J.
    Papadopoulos, Kyriakos P.
    Tolcher, Anthony W.
    Teitelbaum, Ursina R.
    Harlacker, Kathleen
    Smith, Lon S.
    Sohal, Davendra
    Rasco, Drew Warren
    Beeram, Muralidhar
    Mehran, Mariam
    Tawashi, Manal
    Drouin, Michel A.
    Wang, James
    Fournel, Marielle
    Maroun, Christiane R.
    Karam, Andre
    Besterman, Jeffrey M.
    Patnaik, Amita
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] A PHASE I, DOSE-ESCALATION STUDY OF MGCD265, A MULTI-TARGETED ORAL TYROSINE KINASE RECEPTOR INHIBITOR, FOR TREATMENT OF ADVANCED SOLID TUMORS
    Hurwitz, H. I.
    Kollmannsberger, C. K.
    Juretic, M.
    Wang, J.
    Fournel, M.
    Bonfils, C.
    Maroun, C.
    Humphrey, R. W.
    Besterman, J.
    Shapiro, G.
    ANNALS OF ONCOLOGY, 2012, 23 : 163 - 163
  • [4] A first in human phase I study of receptor tyrosine kinase (RTK) inhibitor MGCD516 in patients with advanced solid tumors.
    Bauer, Todd Michael
    Adkins, Douglas
    Schwartz, Gary K.
    Werner, Theresa Louise
    Alva, Ajjai Shivaram
    Hong, David S.
    Carvajal, Richard D.
    Saleh, Mansoor N.
    Bazhenova, Lyudmila
    Goel, Sanjay
    Eaton, Keith D.
    Siegel, Robert D.
    Wang, Ding
    Lauer, Richard C.
    Neuteboom, Saskia T. C.
    Faltaos, Demiana
    Chen, Isan
    Christensen, James
    Chao, Richard C.
    Heist, Rebecca Suk
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors
    Amita Patnaik
    Shirish Gadgeel
    Kyriakos P. Papadopoulos
    Drew W. Rasco
    Naomi B. Haas
    Hirak Der-Torossian
    Demiana Faltaos
    Diane Potvin
    Vanessa Tassell
    Manal Tawashi
    Richard Chao
    Peter J. O’Dwyer
    Targeted Oncology, 2022, 17 : 125 - 138
  • [6] A first-in-human phase 1/1b study of receptor tyrosine kinase (RTK) inhibitor, MGCD516, in patients with advanced solid tumors
    Schwartz, G.
    Adkins, D.
    Heist, R.
    Werner, T.
    Abbott, M.
    Barber, S.
    Slusarz, K.
    Agarwal, N.
    Neuteboom, S.
    Faltaos, D.
    Chen, I.
    Christensen, J.
    Chao, R.
    Bauer, T.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S78 - S78
  • [7] A Study of MGCD516, a Receptor Tyrosine Kinase (RTK) Inhibitor, in Molecularly Selected Patients with NSCLC or Other Advanced Solid Tumors
    Werner, Theresa
    Heist, Rebecca
    Carvajal, Richard
    Adkins, Douglas
    Alva, Ajjai
    Goe, Sanjay
    Hong, David
    Bazhenova, Lyudmila
    Saleh, Mansoor
    Siegel, Robert
    Kyriakopoulos, Christos
    Blakely, Collin
    Eaton, Keith
    Lauer, Richard
    Wang, Ding
    Schwartz, Gary
    Neuteboom, Saskia
    Potvin, Diane
    Faltaos, Demiana
    Chen, Isan
    Christensen, James
    Levisetti, Matteo
    Chao, Richard
    Bauer, Todd
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1068 - S1069
  • [8] A first-in-human phase I/Ib study of receptor tyrosine kinase (RTK) inhibitor, MGCD516, in patients with advanced solid tumors.
    Schwartz, Gary K.
    Adkins, Douglas
    Heist, Rebecca Suk
    Abbott, Maura
    Barber, Stephanie L.
    Chao, Richard C.
    Neuteboom, Saskia T. C.
    Chen, Isan
    Christensen, James
    Bauer, Todd Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR: Dose-escalation phase I study
    Kollmannsberger, Christian K.
    Hurwitz, Herbert
    Cleary, James M.
    Strickler, John H.
    Drouin, Michel A.
    Juretic, Manuela
    Hunt, Wendy
    Reid, Gregory K.
    Maroun, Christiane R.
    Bonfils, Claire
    Wang, James
    Karam, Andre
    Besterman, Jeffrey M.
    Mehran, Mariam
    Shapiro, Geoffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Daily administration of MGCD265 to patients with solid tumors in a dose-escalation phase 1 study (study 265-101)
    Drouin, M. A.
    Kollmannsberger, C. K.
    Uronis, H. E.
    Martell, R. E.
    Wang, J.
    Dubay, M.
    Dupont, I.
    Besterman, J. M.
    Hurwitz, H.
    Shapiro, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345